This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 155 entries.
Botanix (ASX:BOT) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 30 June 2021. Key highlights from this period include: Successful launch of the BTX 1702 rosacea clinical study, currently under COVID related restrictions, with sites initiated in Australia and New Zealand start up pending Encouraging results […]
Skin specialists have reported an increase in people seeking treatment for skin conditions as a result of mandatory mask wearing in Australia due to COVID-19. Dubbed ‘maskne’, the condition includes acne, rosacea flare ups, perioral dermatitis, and folliculitis, all of which are aggravated by substances such as oil, bacteria, and dead skin cells becoming trapped […]
Botanix Pharmaceuticals has today updated the market with plans for its Atopic Dermatitis (AD) clinical program. This follows important recent learnings on drug dose and formulation design of synthetic CBD in dermatitis applications, together with positive data from a new pilot study conducted in canines with AD. Canine atopic dermatitis is clinically and immunologically similar […]
Botanix Pharmaceuticals President and Executive Chairman, Vince Ippolito, and Executive Director, Matt Callahan, hosted an investor conference call on Friday 7 May 2021. You may listen to the audio file here:
Botanix Pharmaceutical’s (ASX:BOT) Executive Director, Matt Callahan, spoke with the Ticker News team yesterday to detail the next phase of our BTX 1801 antimicrobial program, which will target nasal decolonisation of Staph aureus in haemodialysis patients.
Botanix Pharmaceuticals has today released an updated investor presentation and registration details for a conference call with our investors and supporters. participants can pre-submit questions to be answered at the end of the call, when registering through the link below. See the updated investor presentation here. Conference call details: Date: Friday, 7 May 2021 Time: […]
Botanix Pharmaceuticals has today released a comprehensive update and presentation on imminent plans for the BTX 1801 antimicrobial platform program. The next phase of development for BTX 1801 will focus on targeting the nasal decolonisation of Staph aureus in haemodialysis patients, which represents a significant market opportunity to prevent bloodstream infections in these patients. Dialysis […]
Botanix Pharmaceutical’s ground-breaking research on the antimicrobial potential of cannabidiol (CBD) has been published by a leading South American academic group in BioRxiv. The BioRxiv article confirms our discovery that synthetic CBD can also kill a select group of Gram-negative bacteria, including the bacteria responsible for the sexually transmitted disease gonorrhoea and the increasingly challenging […]
Senior writer for Freethink, B.David Zarley, has published a feature article titled ‘Can CBD be the Next Superbug Slayer?’ It examines the importance Botanix’s research into the antimicrobial potential of cannabidiol and includes comments from Dr Mark Blaskovich, Director of UQ’s IMB Centre for Superbug Solutions and collaborator on our BTX 1801 antimicrobial research. Read […]
Addressing the pressing global emergency of antimicrobial resistance (AMR) is central to our work at Botanix Pharmaceuticals (ASX:BOT). Our BTX 1801 antimicrobial platform program is designed to offer novel treatments and solutions, leveraging the unique power of synthetic CBD. This week, the ABC in Australia aired the final episode of its three-part Invisible Wars documentary […]
